Isis Pharmaceuticals Inc. (ISIS) is in the Pharma Industry

• Sort by

• Glaxo to Buy Biotech Sirtris in $720 Mln Deal

  By Ransdell Pierson NEW YORK (Reuters UK) - GlaxoSmithKline GSK said on Tuesday it had agreed to buy biotechnology company Sirtris Pharmaceuticals Inc SIRT for $720 million (360.69 million pounds) in cash, in hopes its medicines that modulate an aging-related family of enzymes will be...

  News items 2008-04-22

  Tags: Glaxo, Type 2, Regulus, Biotechnology, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc., Isis Pharmaceuticals Inc., Sirtris Pharmaceuticals Inc.

• Glaxo Boosts Biotech With Regulus Deal

  By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK boosted its position in biotech on Thursday by signing a deal that could be worth up to $600 million (303 million pounds) with Regulus Therapeutics, taking it into the hot area of RNA technology. The tie-up covers...

  News items 2008-04-17

  Tags: RNA, Inflammation, Regulus Therapeutics, MicroRNAs, Biotechnology, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc., Isis Pharmaceuticals Inc.

Additional Resources

• Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases

  CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods...

  Articles 2008-05-06

• FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen

  Isis to Host Conference Call Today at 8 a.m. EDT CARLSBAD, Calif. and CAMBRIDGE, Mass., April 25 /PRNewswire/ -- Isis Pharmaceuticals, Inc. and Genzyme Corp. announced today that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction...

  Articles 2008-04-25

• Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis

  CARLSBAD, Calif., April 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. presented the results of two studies designed to assess the impact of lowering apoB-100 on atherosclerosis at the 2008 Annual Atherosclerosis, Thrombosis and Vascular Biology ATVB Conference in Atlanta, Georgia. The data were presented in a poster entitled...

  Articles 2008-04-18

• GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases

  Companies Announce Significant microRNA Therapeutics Collaboration LONDON & PHILADELPHIA & CARLSBAD, Calif. -- GlaxoSmithKline GSK and Regulus Therapeutics LLC Regulus today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus is...

  Articles 2008-04-17

• Regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance

  CARLSBAD, Calif. & CAMBRIDGE, Mass. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call this morning, Thursday, April 17, at 8:00 a.m. ET to discuss its new alliance with GlaxoSmithKline. ...

  Articles 2008-04-17

• Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

  Isis Will Host a Conference Call on Monday, April 14, at 8:30 a.m. E.T. at http://www.isispharm.com CARLSBAD, Calif., April 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced additional results from its ongoing Phase 2 open-label extension OLE study of mipomersen in patients with familial hypercholesterolemia FH. ...

  Articles 2008-04-14

• Bristol-Myers Squibb Selects Isis Drug Targeting Pcsk9 As Development Candidate For Prevention And Treatment Of Cardiovascular Disease

  Isis To Receive $2 Million Milestone Payment CARLSBAD, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb Company has selected a compound from the companies' collaboration as a development candidate. As a result, Isis will receive a $2 million milestone...

  Articles 2008-04-08

• isis pharmaceuticals inc. Review in Progress.

  M2 PRESSWIRE-14 March 2008-The Maybach Review: Isis Pharmaceuticals Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:14032008 MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Investors wanting to know the truth about investing...

  Articles 2008-03-14

• Isis Reports Financial Results and Highlights for Fiscal year 2007

  * 2007 Net Operating Loss 54% Lower than 2006 * Successful Execution of Partnership Strategy Provides Nearly $450 Million in Cash and Committed Cash * 2008 Projected Net Operating Loss Less than $15 Million * 2008 Projected Year-End Cash Greater than $450 Million ...

  Articles 2008-03-13

• Global Market Perspective vs. Isis Pharmaceuticals, Inc.

  M2 PRESSWIRE-13 March 2008-Market Review: Global Market Perspective vs. Isis Pharmaceuticals, Inc.C1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 Streetinvesting.com has now resumed our progressive review of Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) after it traded up less than 1% Thursday, early in...

  Articles 2008-03-13

• Introduces Isis Pharmaceuticals to our Bluechips Portfolio.

  M2 PRESSWIRE-13 March 2008-Stock Targets: Introduces Isis Pharmaceuticals to our Bluechips PortfolioC1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 International Stock Targets is a world renowned independent research firm, based in Johannesburg, South Africa. Along with walking investors through the whole...

  Articles 2008-03-13

• QED International Associates Announces Changes to the HealthShares™ Composite and HealthShares™ Cancer Indexes

  NEW YORK, March 6 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange-Traded Funds, today announced that effective at the opening of trading on March 10, 2008, ISIS Pharmaceuticals will replace Pharmion Corp. in the...

  Articles 2008-03-06

• Antisense Therapeutics Ltd Licenses ATL1102 to Teva Pharmaceutical Industries Ltd.

  -- ATL1102 Licensed to Teva Pharmaceutical Industries Ltd.-- ANP to Complete Current Phase IIa Trial -- Results Due Mid-Year-- Teva to Fund and Perform All Future Development of ATL1102 Beyond Current Trial Antisense Therapeutics Ltd. (ASX: ANP) announced on February...

  Articles 2008-02-20

• OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer

  Data presented at the 2008 Genitourinary Cancers Symposium VANCOUVER, Feb. 15 /PRNewswire/ -- OncoGenex Technologies Inc. announced today that the Company's lead cancer drug candidate, OGX-011, also referred to as custirsen, was well-tolerated in combination with either docetaxel or mitoxantrone administered as second-line chemotherapy in patients with...

  Articles 2008-02-15

• Has added isis pharmaceuticals inc. to their watch list.

  M2 PRESSWIRE-13 February 2008-investorIM: Has added Isis Pharmaceuticals Inc. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:13022008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate....

  Articles 2008-02-13

• Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis' Pathogen Identification Technology

  CARLSBAD, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that its majority-owned subsidiary, Ibis Biosciences, Inc. Ibis, has been awarded two new Phase 2 Small Business Innovation Research SBIR grants and a new government contract totaling up to approximately $2.8 million. The SBIR grants awarded...

  Articles 2008-02-12

• Has added isis pharmaceuticals inc. to their watch list.

  M2 PRESSWIRE-12 February 2008-The Maybach Review: Has added Isis Pharmaceuticals Inc. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:12022008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers,...

  Articles 2008-02-12

• Isis Pharmaceuticals, Inc. Receives Progressive Following.

  M2 PRESSWIRE-12 February 2008-Market Review: Isis Pharmaceuticals, Inc. Receives Progressive FollowingC1994-2008 M2 COMMUNICATIONS LTD RDATE:12022008 Streetinvesting.com has now resumed our progressive review of Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) after it traded up 1% Tuesday, late in the morning with...

  Articles 2008-02-12